Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Globe Newswire•24/09/2026•07:00 ET
0
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November
CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December
Get started
Create a free account to read the full story and Whiz Insights.